Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01673659 · ClinicalTrials.gov registry record · Phase 3
A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)
A Phase 3 study, sponsored by Padagis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,220
- Enrollment target
NCT01673659 is a Phase 3 study that has completed, run by Padagis. The registered enrollment target is 1,220 participants.
The verdict
NCT01673659, a Phase 3 study, has completed, sponsored by Padagis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,220 participants
- Enrollment target
Study Summary
The objectives of this study is to demonstrate bioequivalence (comparable safety and efficacy) of the Test product to the Reference in the treatment of subjects seasonal allergic rhinitis.
Interventions
- DRUG Placebo nasal spray
- DRUG Mometasone furoate
- DRUG Nasonex Nasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,220 participants |
| Start Date | 2012-08 |
| Est. Completion | 2012-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01673659
The ClinicalTrials.gov registry entry for NCT01673659 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Padagis, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo nasal spray is the first listed.
NCT01673659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01673659 about?
NCT01673659 is a clinical study titled "A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)". The objectives of this study is to demonstrate bioequivalence (comparable safety and efficacy) of the Test product to the Reference in the treatment of subjects seasonal allergic rhinitis.
What is the current status of trial NCT01673659?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,220 participants. The study started on 2012-08. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01673659?
The interventions under investigation include: Placebo nasal spray (DRUG), Mometasone furoate (DRUG), Nasonex Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT01673659?
This trial is sponsored by Padagis, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.